Settlements between originators and generics can benefit consumers, claims research

A recent study claims that US consumers and the federal government have saved around $25.5 billion on the cost of drugs since 2005 due to patent dispute settlements between pharmaceutical originators and generic manufacturers. While ‘pay-for-delay’…

Get unlimited access to all IAM content